acquired
Stage
2013
Founded
2
Investors
About
LogicBio was a clinical-stage genetic medicine company focused on developing gene therapies for rare diseases, utilizing its proprietary gene editing and gene delivery platforms. The company was acquired by Alexion, AstraZeneca's rare disease group, in 2022.
Explore LogicBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.